Table 1

Characteristics of children enrolled in the HIV programs at the time of registration and their outcomes.

<18 months

18–59 months

≥ 60 months

Total


Number of children registered

69 (5.9%)

479 (41.0%)

620 (53.1%)

1168


Gender

Female

33 (47.8%)

230 (48.0%)

292 (47.1%)

555 (47.5%)


WHO or CDC stage

WHO 1/2 or CDC stage N/A/B

34 (50.0%)

310 (64.7%)

395 (63.7%)

739 (63.3%)

WHO 3/4 or CDC C

34 (50.0%)

(n = 68)

169 (35.3%)

225 (36.3%)

428 (36.7%)

(n = 1167)


CD4 cells/mm3, median (IQR)

753 (338–1280)

(n = 40)

643 (310–1049)

(n = 353)

245 (40–599)

(n = 561)

410 (94–818)

(n = 954)


CD4 cells/mm3

<50

2 (5.0%)

22 (6.2%)

149 (26.6%)

173 (18.1%)

50–350

8 (20.0%)

75 (21.3%)

175 (31.2%)

258 (27.0%)

>350

30 (75.0%)

256 (72.5%)

237 (42.2%)

523 (54.8%)


CD4%, median (IQR)

18.71(12.44–23.75)

(n = 48)

18 (10–24.8)

(n = 415)

9.41 (2.76–18.72)

(n = 399)

14.47 (5.33–23)

(n = 862)


CD4% group3

<15.0%

16 (33.3%)

164 (39.5%)

260 (65.2%)

440 (51.0%)

15–24.9%

21 (43.7%)

148 (35.7%)

81 (20.3%)

250 (29.0%)

≥ 25.0%

11 (22.9%)

103 (24.8%)

58 (14.5%)

172 (20.0%)


Weight for height*

≥ -2 z-score

33 (55.0%)

366 (81.0%)

435 (76.7%)

834 (77.3%)

<-2 and ≥ -3 z-score

12 (20.0%)

53 (11.7%)

82 (14.5%)

147 (13.6%)

<-3 z-score

15 (25.0%)

33 (7.3%)

50 (8.8%)

98 (9.1%)


Weight for age

≥ -2 z-score

29 (42%)

153 (31.9%)

127 (20.5%)

309 (26.5%)

<-2 and ≥ -3 z-score

12 (17.4%)

176 (36.7%)

287 (46.4%)

475 (40.7%)

<-3 z-score

28 (40.6%)

150 (31%)

205 (33.1%)

383 (32.8%)


Year of admission

2003

2 (2.9%)

53 (11.1%)

36 (5.8%)

91 (7.8%)

2004

13 (18.8%)

117 (24.4%)

183 (29.5%)

313 (26.8%)

2005

17 (24.6%)

123 (25.7%)

165 (26.6%)

305 (26.1%)

2006

19 (27.5%)

109 (22.8%)

130 (21.0%)

258 (22.1%)

2007

18 (26.1%)

77 (16.1%)

106 (17.1%)

201 (17.2%)


Started ART§

42 (60.9%)

278 (58.0%)

394 (63.6%)

714 (61.1%)


Follow up time in days, median (IQR)

333 (134–840)

755 (349–1207)

750.5 (320.5–1193)

733.5 (314.5–1182.5)


Outcome on study termination:

Alive and in active follow up

40 (58.0%)

361 (75.4%)

448 (72.3%)

849 (72.7%)

Dead

15 (21.7%)

37 (7.7%)

53 (8.6%)

105 (9.0%)

Lost to follow up*

8 (11.6%)

42 (8.8%)

63 (10.2%)

113 (9.7%)

transferred 6 (8.7%)

39 (8.1%)

56 (9.0%)

101 (8.6%)


WHO: World Health Organization; CDC: Centre for Disease Control; IQR: inter-quartile range; ART: anti-retroviral treatment

last contact with clinic > 3 months

§32 patients switched to second line therapy during the study period

CD4 count and %: measured within 120 days after date of registration or HIV status confirmation

Raguenaud et al. BMC Pediatrics 2009 9:54   doi:10.1186/1471-2431-9-54

Open Data